biomarin.com - BMRN Profit before deduction of interest, taxes, depreciation and amortization

Is it worth investing in the defensive asset BioMarin (BMRN), whose demand is recession-proof? Current operating profit in cash provides an objective answer, where the value 984.03 describes the current level. BioMarin Pharmaceutical relies on immense pricing power within the orphan drug segment, yet faces geopolitical risks regarding international drug registration and challenges with raw material logistics.

biomarin.com (BMRN) Operating profit EBITDA: for the period 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for BioMarin (BMRN)

- stock value and consensus price forecast:

Market Chart BioMarin Corp|BMRN - Consensus Target

- issuer market value details:

Market Valuation BioMarin|BMRN - Enterprise Value

- book capitalization indicators:

Net Asset Value per Share BioMarin|BMRN - Book Capitalization|Capitalization to Book Value Ratio biomarin.com|BMRN - Cumulative Company Assets

- business debt structure and liquidity details:

- earnings and market multiples details:

BMRN - Company Net Income|Future Profit BioMarin Pharmaceutical|BMRN - P/E Multiple|Forward P/E Multiple biomarin.com|BMRN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioMarin|BMRN - Operating profit EBITDA|Net earnings per share for the last four quarters BioMarin|BMRN - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomarin.com|BMRN - Earnings per share growth in current year|Expected earnings per share growth for next year BioMarin Pharmaceutical

Summary company analytics:BioMarin Corp

The reliability of an equity asset is determined by the business's ability to generate real cash flow. This metric measures the actual daily cash inflow, excluding non-cash GAAP revaluations. For BioMarin Pharmaceutical (BMRN), the value 984.03 reflects the commercialization efficiency of the drug Voxzogo and cost control. Growth in this indicator confirms the monetization of the orphan pipeline. An analysis of the operating profit summary allows for an objective assessment of the company's intrinsic value.

Who BioMarin Pharmaceutical competes with

Operating income before deduction of amortization Vertex Corp (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - Operating profit EBITDA|Operating profit before amortization COGT (Cogent Corp)|Operating profit before deduction of amortization XERS (Xeris Biopharma)|KROS (kerostx.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Kamada Corp - Operating profit EBITDA|Income before deduction of interest, taxes and amortization FULC (Fulcrum Corp)|ABEO: Operating profit EBITDA|Mereo BioPharma Group plc (MREO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Protalix BioTherapeutics, Inc.|PLRX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Applied Therapeutics (APLT)|Operating profit before deduction of amortization Aileron Therapeutics RNTX|Operating profit EBITDA GELS (Gelteq)|Operating profit EBITDA Aytu BioPharma Inc AYTU|Chemomab - Operating profit EBITDA|SRXH: Profit before payment of interest, taxes and amortization|PLRZ: Operating profit EBITDA|AEZS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Cyclo Therapeutics|Profit before interest, taxes and amortization Inozyme INZY|Profit before payment of interest, taxes and amortization Reneo Pharmaceuticals, Inc. (RPHM)|Operating profit before deduction of amortization COSCIENS Biopharma Inc CSCI